CN Patent
CN102271683B — 恶性血液病的治疗
Assigned to Gilead Calistoga LLC · Expires 2014-07-09 · 12y expired
What this patent protects
本发明提供涉及用于治疗恶性血液病和炎性疾病的新治疗策略的方法。具体而言,所述方法包括施用式A化合物,其中R是H、卤素或C1-C6烷基;R’是C1-C6烷基;或其可药用盐;和任选地可药用赋形剂。
USPTO Abstract
本发明提供涉及用于治疗恶性血液病和炎性疾病的新治疗策略的方法。具体而言,所述方法包括施用式A化合物,其中R是H、卤素或C1-C6烷基;R’是C1-C6烷基;或其可药用盐;和任选地可药用赋形剂。
Drugs covered by this patent
- Imbruvica (ibrutinib) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.